Open-label, randomized, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma.

KI-AV0 sites110 target enrollmentTBD

ConditionsCetuximab, non-small lung carcinoma, cisplation, radiotherapy, locally advanced

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cetuximab, non-small lung carcinoma, cisplation, radiotherapy, locally advanced
Sponsor: KI-AV
Enrollment: 110
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

KI-AV

Eligibility Criteria

Inclusion Criteria

•1\. \>\= 18 years of age;
•2\. Histologically or cytologically confirmed diagnosis of NSCLC;

Exclusion Criteria

•1\. Concurrent active malignancy other than localized, non\-melanoma skin cancer or carcinoma\-in\-situ of the cervix (unless definitive treatment was completed 5 years or more before study entry and the patient has remained disease free);

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

Not Applicable

A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimensChronic Lymphocytic Leukemia (CLL)

NL-OMON23205HOVON data center70

Active, not recruiting

Phase 2

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeGlioblastoma Multiforme, Adult

NCT04762069CNS Pharmaceuticals, Inc.252

Recruiting

Phase 2

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal CancerColorectal Cancer

NCT06293014Henan Cancer Hospital224

Withdrawn

Phase 4

A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid ArthritisRheumatoid Arthritis

NCT00783536Wyeth is now a wholly owned subsidiary of Pfizer

Not yet recruiting

Phase 2

Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma

NL-OMON32353Antoni van Leeuwenhoek Ziekenhuis112